| Dual PPAR α/γ agonist Saroglitazar improves liver histopathology and biochemistry in experimental NASH models MR Jain, SR Giri, B Bhoi, C Trivedi, A Rath, R Rathod, R Ranvir, S Kadam, ... Liver International 38 (6), 1084-1094, 2018 | 191 | 2018 |
| Melatonin protects against lipid‐induced mitochondrial dysfunction in hepatocytes and inhibits stellate cell activation during hepatic fibrosis in mice N Das, A Mandala, S Naaz, S Giri, M Jain, D Bandyopadhyay, RJ Reiter, ... Journal of pineal research 62 (4), e12404, 2017 | 158 | 2017 |
| The PPAR α/γ agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease DP Kumar, R Caffrey, J Marioneaux, PK Santhekadur, M Bhat, C Alonso, ... Scientific reports 10 (1), 9330, 2020 | 107 | 2020 |
| Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid‐lowering and insulin‐sensitizing effects in preclinical models MR Jain, SR Giri, C Trivedi, B Bhoi, A Rath, G Vanage, P Vyas, R Ranvir, ... Pharmacology Research & Perspectives 3 (3), e00136, 2015 | 82 | 2015 |
| Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression SK Bhavsar, S Singh, S Giri, MR Jain, DD Santani Journal of ethnopharmacology 124 (3), 426-433, 2009 | 66 | 2009 |
| Discovery of a potent and orally efficacious TGR5 receptor agonist S Agarwal, A Patil, U Aware, P Deshmukh, B Darji, S Sasane, ... ACS medicinal chemistry letters 7 (1), 51-55, 2016 | 34 | 2016 |
| Design and synthesis of novel oxazole containing 1, 3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists H Pingali, M Jain, S Shah, P Makadia, P Zaware, A Goel, M Patel, S Giri, ... Bioorganic & medicinal chemistry 16 (15), 7117-7127, 2008 | 29 | 2008 |
| Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents P Raval, M Jain, A Goswami, S Basu, A Gite, A Godha, H Pingali, S Raval, ... Bioorganic & medicinal chemistry letters 21 (10), 3103-3109, 2011 | 27 | 2011 |
| Decrease in serum matrix metalloproteinase-9 and matrix metalloproteinase-3 levels in Zucker fa/fa obese rats after treatment with swertiamarin HB Vaidya, S Giri, M Jain, RK Goyal Experimental & Clinical Cardiology 17 (1), 12, 2012 | 25 | 2012 |
| Development and validation of a HPLC-UV method for simultaneous determination of strobilurin fungicide residues in tomato fruits followed by matrix solid-phase dispersion (MSPD) TN Rao, A Ramesh, T Parvathamma, G Suresh Indian Journal of Scientific Research 3 (1), 113-118, 2012 | 22 | 2012 |
| Effect of structurally constrained oxime–ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists P Makadia, SR Shah, H Pingali, P Zaware, D Patel, S Pola, B Thube, ... Bioorganic & medicinal chemistry 19 (2), 771-782, 2011 | 22 | 2011 |
| Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection PD Yadav, S Kumar, K Agarwal, M Jain, DR Patil, K Maithal, B Mathapati, ... BioRxiv, 2021.02. 02.429480, 2021 | 18 | 2021 |
| Determination of indirect tensile strength of bituminous concrete mix prepared using stone dust and cement as filler materials L Gupta, G Suresh Materials for Sustainable Infrastructure: Proceedings of the 1st GeoMEast …, 2018 | 17 | 2018 |
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl) hexyl]-2-methyl-1, 3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent H Pingali, M Jain, S Shah, S Basu, P Makadia, A Goswami, P Zaware, ... Bioorganic & medicinal chemistry letters 18 (20), 5586-5590, 2008 | 17 | 2008 |
| Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes S Agarwal, S Sasane, J Kumar, P Deshmukh, H Bhayani, P Giri, S Giri, ... Bioorganic & Medicinal Chemistry Letters 28 (10), 1849-1852, 2018 | 16 | 2018 |
| Identification of an orally efficacious GPR40/FFAR1 receptor agonist S Agarwal, S Sasane, P Deshmukh, B Rami, D Bandyopadhyay, P Giri, ... ACS Medicinal Chemistry Letters 7 (12), 1134-1138, 2016 | 15 | 2016 |
| Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency. S Giri, SK Mahajan, R Sen, A Sharma The Journal of the Association of Physicians of India 50, 1245-1249, 2002 | 12 | 2002 |
| Synergistic compositions MR Jain, G Suresh, HM Kothari, K Banerjee, R Kachhiya US Patent 9,656,954, 2017 | 11 | 2017 |
| Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification P Zaware, SR Shah, H Pingali, P Makadia, B Thube, S Pola, D Patel, ... Bioorganic & medicinal chemistry letters 21 (2), 628-632, 2011 | 11 | 2011 |
| Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes S Pola, SR Shah, H Pingali, P Zaware, B Thube, P Makadia, H Patel, ... Bioorganic & Medicinal Chemistry 35, 116071, 2021 | 10 | 2021 |
